These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23216430)

  • 1. The use of cost-effectiveness analysis for pediatric immunization in developing countries.
    Gauvreau CL; Ungar WJ; Köhler JC; Zlotkin S
    Milbank Q; 2012 Dec; 90(4):762-90. PubMed ID: 23216430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review of the incremental costs of interventions that increase immunization coverage.
    Ozawa S; Yemeke TT; Thompson KM
    Vaccine; 2018 Jun; 36(25):3641-3649. PubMed ID: 29754699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Countdown to 2015: tracking donor assistance to maternal, newborn, and child health.
    Powell-Jackson T; Borghi J; Mueller DH; Patouillard E; Mills A
    Lancet; 2006 Sep; 368(9541):1077-87. PubMed ID: 16997662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low- and middle-income countries.
    Munk C; Portnoy A; Suharlim C; Clarke-Deelder E; Brenzel L; Resch SC; Menzies NA
    BMC Health Serv Res; 2019 Oct; 19(1):741. PubMed ID: 31640687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we use contingent valuation to assess the demand for childhood immunisation in developing countries?: a systematic review of the literature.
    Yeung RY; Smith RD
    Appl Health Econ Health Policy; 2005; 4(3):165-73. PubMed ID: 16309334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
    Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
    Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.
    Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K
    JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of quality vaccines: policies of a non-government organization.
    Poore P
    Vaccine; 1992; 10(13):958-60. PubMed ID: 1471421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic aspects of health care in relation to vaccination programs].
    Kuszewski K
    Przegl Epidemiol; 2003; 57 Suppl 1():9-13. PubMed ID: 12920999
    [No Abstract]   [Full Text] [Related]  

  • 13. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
    Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
    Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund.
    Martin JF; Marshall J
    Vaccine; 2003 Jan; 21(7-8):587-92. PubMed ID: 12531322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.
    Plosker GL
    Pharmacoeconomics; 2011 Nov; 29(11):989-1009. PubMed ID: 21988293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluations of rotavirus immunization for developing countries: a review of the literature.
    Tu HA; Woerdenbag HJ; Kane S; Rozenbaum MH; Li SC; Postma MJ
    Expert Rev Vaccines; 2011 Jul; 10(7):1037-51. PubMed ID: 21806398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The global value of vaccination.
    Ehreth J
    Vaccine; 2003 Jan; 21(7-8):596-600. PubMed ID: 12531324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.